Risk factors

Home Depot faces heightened compliance and reputational risks regarding responsible sourcing of raw materials like timber and minerals.

Clinical-stage biopharmaceutical company focused on developing VT-1953 and VT-1908 following a corporate merger. Faces substantial operating losses, lack of commercial revenue, and significant capital raising requirements. Insider ownership is highly concentrated at over seventy-four percent.

Substantial ongoing net losses drive the risk profile, dominated by single-product concentration in HeartFlow FFR CT Analysis.

New compliance risks cover artificial intelligence regulations, international trade tariffs, and medical device recalls for the Swoop system. Financial risk numbers updated, including federal net operating loss carryforwards rising to $222.0 million for Hyperfine and $16.4 million for Liminal.

Lifeward faces new manufacturing risks after bringing ReWalk production in-house and terminating its contract with Sanmina.

Moleculin faces intense dependency on single-source suppliers for drug candidates like Annamycin and requires continuous external funding to survive.

Client concentration grew with top ten clients generating 58% of 2025 revenue and financial services reaching 54%. Managed Service Providers and Global Capability Centers pressured gross margins down and dropped client retention. Artificial intelligence adoption and compliance costs emerged as new strategic operational risks.

Marker now emphasizes outsourced manufacturing: no cGMP facility, BCM reliance, and Cellipont's MT-601 work ahead of a 2026 lymphoma trial.

Customer concentration intensified, with four customers driving 95.4% of consolidated net revenues in 2025 compared to 80.2% in 2024. Macroeconomic and pricing risks were added as new factors making revenues difficult to forecast.

Energy Vault expanded disclosures on emerging markets, tariff escalations, tax carryforwards, and backlog definitions. Increased share counts for warrants and equity plans escalated dilution risks.

The risk section is dominated by the recent US commercial launch of CGuard Prime and upcoming trials for SwitchGuard NPS. Increased disclosures focus on US sales execution, clinical trial compliance, single-source component vulnerabilities, and Israeli operational dependencies.

The risk section centers on OSS’s strategic shift to core edge-computing systems after selling Bressner.